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Hypothesis: Limited information is available on late complications
of multimodality therapy for locally advanced esophageal cancer.
This study focuses on postesophagectomy benign pleural and peri-
cardial complications to determine their prevalence, temporal pat-
tern, and treatment, and their association with induction chemora-
diotherapy and influence on survival.
Methods: Between March 1987 and November 2001, 291 patients
with clinical stage IIA esophageal cancer underwent esophagec-
tomy; 106 received induction chemoradiotherapy. A propensity
score incorporating clinical stage and histopathology was used to
identify 100 matched pairs of induction chemoradiotherapy and
surgery-only patients. Among these, occurrence of pleural effusion,
pericardial effusion, and pericarditis was ascertained by follow-up.
Time-related occurrence, risk factors, and association with survival
were assessed by repeated-events analyses.
Results: During follow-up, 61 induction chemoradiotherapy pa-
tients experienced at least one pleural or pericardial complication, as
did 46 propensity-matched surgery-only patients. Most occurred
within 1 year, with 1-year freedom from occurrence only 34% after
induction chemoradiotherapy and 59% after surgery only (p 
0.02). Risk of pleural effusion was nearly twice as great (hazard
ratio 1.7, p  0.0004) and pericardial complications 5 times greater
(hazard ratio 5.3, p  0.0005) after induction chemoradiotherapy
than after surgery alone. Complications after induction chemoradio-
therapy required intervention somewhat more frequently (58% ver-
sus 47%, p  0.18), although they did not diminish subsequent
survival (p  0.8).
Conclusions: Benign pleural and pericardial complications occur
surprisingly frequently after esophagectomy, particularly when in-
duction chemoradiotherapy is employed. This must be factored into
discussions of morbidity for multimodality treatment strategies for
locally advanced esophageal cancer and should be considered dis-
tinct from acute toxicity of induction chemoradiotherapy reported.
Key Words: Pleural effusion, Pericardial effusion, Pericarditis,
Multimodality therapy.
(J Thorac Oncol. 2009;4: 395–403)
Although safety of esophageal resection for carcinoma hassteadily improved,1 it remains one of the most morbid
elective operations. Adding to the procedure’s magnitude has
been the use of induction chemoradiotherapy for locally
advanced cancer,2–4 which has affected both short- and long-
term outcomes.5,6
An unexpected clinical observation was that patients
treated with induction chemoradiotherapy frequently pre-
sented after esophagectomy with benign pleural and pericar-
dial complications. Consequently, we designed a study to (1)
document occurrence, temporal pattern, and treatment of
these complications in comparable patients, (2) test the hy-
pothesis that they occurred more frequently in patients re-
ceiving induction chemoradiotherapy, and (3) assess their
influence on survival.
PATIENTS AND METHODS
Patients
Between March 1987 and November 2001, 291 patients
with clinical stage IIA or greater carcinoma of the esophagus
underwent esophagectomy via thoracotomy at Cleveland
Clinic.7 Of these, 106 (36%) received induction chemoradio-
therapy. Patient and tumor characteristics and operative de-
tails were extracted from the Esophagectomy Database,
which has been approved for use in research by the Institu-
tional Review Board, with patient consent waived (Table 1).
Patients selected for induction chemoradiotherapy were gen-
erally those with locally advanced cancers. This group of
patients was deemed to have sufficient cardiopulmonary re-
serve to tolerate multimodality therapy.
Induction Chemoradiotherapy
Over the duration of the study, 3 main induction che-
moradiotherapy regimens were used. The 2 most common
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were (1) 2 cycles of cisplatin (20 mg/m2/d) and 5-fluorouracil
(1000 mg/m2/d), both given as continuous intravenous infu-
sions for 4 days, with concomitant hyperfractionated radia-
tion (150 cGy bid) to the mediastinum to a total dose of 4500
cGy, all administered 1 month before surgery8; and (2) the
same protocol with a 24-hour intravenous infusion of pacli-
taxel (175 mg/m2) in place of 5-fluorouracil.9 A lesser used
regimen consisted of 1 cycle of cisplatin and 5-fluorouracil
along with hyperfractionated radiation of 3000 cGy.10 Pa-
tients tolerating this therapy and without evidence of disease
progression proceeded to esophagectomy, usually within 6
weeks of completion of chemoradiotherapy.10 We attempted
to adjust for small variations in doses and dosing schedules in
our multivariable analyses.
Some patients received postoperative chemoradiother-
apy, similar to the preoperative regimen, with adjustments for
amount of preoperative radiation.8–11 Acute toxicities of these
chemoradiotherapy regimens have been reviewed else-
where.8–10
Benign Pleuropericardial Complications
By medical record examination and systematic struc-
tured interview of patients and their families, all pleural and
pericardial complications (benign or malignant), their date of
occurrence, and management were identified—pleural effu-
sion, chylothorax, empyema, pericardial effusion, and peri-
carditis. This study focuses on benign pleural and pericardial
effusions and pericarditis, defined as follows:
Y Benign pleural effusion: Pleural fluid identified on rou-
tine or symptom-directed chest radiogram, deemed by
attending surgeon or oncologist to be new or to represent
a substantial increase from initial postoperative studies,
and for which investigation revealed no evidence of
malignancy, hemothorax, chylothorax, or empyema. Ef-
fusions without cytology were considered benign if
follow-up radiograms demonstrated either no change or
resolution, and there was no evidence of cancer recur-
rence elsewhere.
Y Benign pericardial effusion: Accumulation of pericar-
dial fluid identified on routine or symptom-directed
chest computed tomography or echocardiography and
for which investigation revealed no evidence of malig-
nancy or infection. Effusions without cytology were
considered benign if follow-up studies demonstrated
either no change or resolution, and there was no evi-
dence of cancer recurrence elsewhere.
Y Benign pericarditis: Inflammation of the pericardium
diagnosed by a combination of physical examination,
electrocardiogram, chest computed tomography, and
echocardiography, for which investigation revealed no
evidence of malignancy.
Analytic Approach
To meaningfully understand these complex data and
develop valid inferences, the following had to be considered.
1. Induction chemoradiotherapy was not administered to
patients in a randomized fashion. Therefore, we had to
simulate a randomized trial by established statistical
methods to generate well-matched study groups.12–14
2. Pleural and pericardial complications occurred over a
time span of several months. Therefore, well-estab-
lished time-related methods were used.15–17
3. These complications were not always singular or mu-
tually exclusive. Therefore, patients continued to be
tracked after occurrence of a complication using re-
peated events analyses.15,17
4. Patients could die of their underlying cancer before a
pleural or pericardial complication. Therefore, death
served as a competing risk with occurrence of these
complications, for which competing risk analysis was
required.18
5. The complications could importantly impact patient sur-
vival; therefore, we estimated the possible increased death
rate attributable to each complication occurrence.19,20
Methodologic Details
Study Design
Induction chemoradiotherapy was not administered to
patients with esophageal cancer in a randomized fashion.
Therefore, consistent with Rubin’s strategy of study design
versus outcome analysis,14 we designed an “approximate
randomized study” to test our hypothesis. Nonparsimonious
logistic regression analysis was used to estimate the propen-
TABLE 1. Patient and Tumor Characteristics and Their
Therapy for All 291 Patients Undergoing Esophagectomy for
Clinical Stage IIA or Greater Carcinoma of the Esophagus
Characteristic
Induction
Chemoradiotherapy
(% of 106)
Surgery Only
(% of 185) p
Male 82 85 0.5
Age at esophagectomy (yr),
mean  SD
60  9 62  10 0.2
Caucasian 93 95 0.5
Clinical stagea 0.002
IIA 34 54
IIB 6 4
III 58 42
IVa 3 0
Histopathologic type
Adenocarcinoma 74 83 0.05
Histologic grade 0.04
Well differentiated 9 6
Moderately differentiated 25 39
Poorly differentiated 65 55
Induction regimen
Radiotherapy 
5-FU/cisplatin
71 —
Radiotherapy  paclitaxel/
cisplatin
29 —
Total radiation dose (Gy),
mean  SD
4200  580 —
Postoperative
chemoradiotherapy
42 35 0.2
a Greene FL, Page DL, Fleming ID, Fritz AG, et al. (Eds.), American Joint
Committee on Cancer Staging Manual, 6th Ed. New York: Springer, 2002, Pp. 91–98.
SD, standard deviation; 5-FU, fluorouracil.
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sity of each patient to receive induction chemoradiotherapy
based on pretreatment clinical stage, histopathologic type,
and histopathologic grade (G), without regard for outcome.
Separate analyses were performed for patients who did (C 
0.65) and did not (C  0.68) receive postoperative chemo-
radiotherapy. From the resulting logistic regression equations,
the probability of receiving induction chemoradiotherapy was
calculated for each patient (propensity score).12,13 This pro-
pensity score was used as the sole variable to match patients
who did versus did not receive induction chemoradiotherapy.
Greedy matching was employed,21 resulting in matching 41
of 45 patients receiving both pre- and postoperative chemo-
radiotherapy and 59 of 61 who received only induction
chemoradiotherapy, a total (by chance) of 100 patients (94%
of such patients), to 100 patients who underwent esophagec-
tomy only without pre-or postoperative chemoradiotherapy
(hereafter designated “surgery only”). Thus, the approximate
randomized study for comparison of outcomes consisted of
these matched groups. Characteristics of these 100 propensity-
matched pairs are given in Table 2. To be conservative in our
comparisons, nonpaired testing was performed, just as would
be the case for a randomized trial.
Follow-Up
Although patients were routinely followed at least
semiannually after esophagectomy, we conducted an addi-
tional cross-sectional follow-up of the matched patients that
included review of clinical records, a mailed questionnaire,
and telephone contact of patients or families failing to re-
spond to the questionnaire. This review, the questionnaire,
and telephone script were approved by Cleveland Clinic’s
Institutional Review Board, the latter two instruments with
patient consent required. Follow-up was 100% complete,
with mean follow-up of 8.3  2.6 years among 34 patients
alive at cross-sectional follow-up.
Complication Occurrence and Temporal Pattern
Benign pleural and pericardial complications did not
occur within a narrow postoperative time span, but were
distributed over several months. Further, they often recurred.
Thus, simple proportions of patients experiencing versus not
experiencing these complications did not accurately reflect
the outcome, nor could simple “terminating event” actuarial
methods be employed, because they do not account for
recurrence of an event. Thus, each benign pleural or pleuro-
pericardial complication was analyzed as (1) time to first
occurrence and (2) a time-related repeated event. A repeat
complication was defined as recurrence beyond 30 days of a
previous complication of that type, independent of treatment.
Kaplan-Meier analysis was used to estimate freedom
from first event,16 and Nelson’s cumulative event analysis
was used for nonparametric estimation of cumulative inci-
dence, expressed as number of complications per patient.17
Multiphase hazard function methodology was used to char-
acterize temporal pattern of occurrence.15 (For additional
details, see http://www.clevelandclinic.org/heartcenter/hazard.)
The primary motivation for use of a multiphase hazard model
was that visual inspection of nonparametric estimates
(Kaplan-Meier and Nelson) revealed a temporal pattern indi-
cating important change in risk across time. Generally, this
implies nonproportional hazards with different risk factors
modulating early and later time periods. The methodology
selected addresses these kinds of data. Using these tech-
niques, freedom from, cumulative incidence of, and hazard
for complications were estimated for benign (a) pleural effu-
sion, (b) pericardial effusion, (c) pericarditis, and (d) the
combination of these.
Influence of Induction Chemoradiotherapy on
Complications
Although patients were propensity matched—rendering
comparisons of outcomes risk adjusted—we nevertheless
performed multivariable parametric analysis of the events to
be sure that another variable confounded with use of induc-
tion chemoradiotherapy did not emerge. For this, the vari-
ables in the Appendix, and the indicator for whether or not
induction chemoradiotherapy had been used, were tested.
These variables included preoperative, postoperative, and
cumulative cycles of chemotherapy and dose of radiation.
Influence of Complications on Subsequent
Survival
To assess the possible influence of these complications
on subsequent survival, we employed modulated-renewal-
process methodology (this industrial technique gave rise to
TABLE 2. Patient and Tumor Characteristics of Propensity-
Matched Patients and Their Therapy
Characteristic
Induction
Chemoradiotherapy
(% of 100)
Surgery Only
(% of 100) p
Male 85 81 0.4
Age at esophagectomy (yr),
mean  SD
60  9 61  11 0.4
Caucasian 93 96 0.4
Clinical stagea 0.6
IIA 34 35
IIB 6 6
III 58 59
IVa 2 0
Histopathologic type
Adenocarcinoma 74 77 0.6
Histologic grade 0.3
Well 10 5
Moderate 27 29
Poor 63 66
Induction regimen
Radiotherapy 
5-FU/cisplatin
73 —
Radiotherapy  paclitaxel/
cisplatin
27 —
Total radiation dose (Gy),
mean  SD
4200  590 —
Postoperative
chemoradiotherapy
41 41 1.0
a Greene FL, Page DL, Fleming ID, Fritz AG, et al. (Eds.), American Joint
Committee on Cancer Staging Manual, 6th Ed. New York: Springer, 2002, Pp. 91–98.
SD, standard deviation; 5-FU, fluorouracil.
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expressions such as “good as new”).19,20 For it, time zero was
reset at each complication. Thus, patients experiencing a first
event were censored at time of occurrence, restarted at a new
time zero, and traced to occurrence of a second event, and so
forth, for each successive event.19
A novel aspect of the present study is that we then
investigated survival within this modulated-renewal context,
treating death as a competing risk. This permitted us to
investigate the possible influence on survival of not only
patient and tumor characteristics and use of induction che-
moradiotherapy, but also of timing and number of postesoph-
agectomy complications. Nonproportionality of risk was
again accommodated by multiphase hazard methodology.15
Presentation
Categorical variables are summarized as frequencies
and percentages and compared by 2 testing or Fisher’s exact
test. Continuous variables are summarized as mean SD and
compared by t test, or summarized as median and interquar-
tile range and compared by Wilcoxon rank sum test. Time-
related event estimates are presented with 68% asymmetric
confidence limits (CL) equivalent to 1 standard error.
RESULTS
Complication Occurrence, Timing, and
Influence of Induction Chemoradiotherapy
During follow-up after esophagectomy, 61 of the 100
propensity-matched induction chemoradiotherapy patients
experienced 118 benign pleural and pericardial complica-
tions, and 46 propensity-matched surgery-only patients expe-
rienced 72 (Table 3). One-year freedom from occurrence of
the first of these complications was only 34% among induc-
tion chemoradiotherapy patients compared with 59% of sur-
gery-only patients (p  0.02, Figure 1). Most complications
occurred within the first postoperative year, although early
risk (hazard) was more protracted in the induction chemora-
diotherapy group (Figure 2A). By 1 year, the number of
complications was 1.3 events per patient in the induction
chemoradiotherapy group, more than twice that after surgery
alone (0.61 events per patient; p  0.02, Figure 2B).
Influence of Induction Chemoradiotherapy on
Individual Complications
The most commonly occurring complication was pleu-
ral effusion (Figure 3), and risk of its occurrence was nearly
twice as great after induction chemoradiotherapy than after
surgery only (hazard ratio, 1.7; CL: 1.5–2.0; p  0.0004).
Risk of a pericardial complication (effusion or, less com-
monly, pericarditis) was more than 5 times as great after
induction chemoradiotherapy (Figure 4; hazard ratio, 5.3; CL:
3.3–8.6; p  0.0005).
Treatment of Complications
Of 118 complications occurring in induction chemora-
diotherapy patients, 68 (58%) required specific therapeutic
interventions, as did 34 of 72 (47%) in surgery-only patients
(p  0.18; Table 4). Eighteen therapeutic interventions were
required in induction chemoradiotherapy patients for 32 be-
nign pericardial complications (56%), as were 3 interventions
for 11 complications (27%) among surgery-only patients
(p  0.16). Overall, 33 induction chemoradiotherapy pa-
tients underwent therapeutic interventions for pleural and
pericardial complications, compared with 24 surgery-only
patients (p  0.2).
Influence of Complications on Subsequent
Survival
Although early survival appeared to be somewhat
worse after a pleural or pericardial complication than before
any such occurrence (Figure 5), nonproportional hazards
evaluation (which can account for “crossing lines” of risk)
indicates that the hazard function for death after each occur-
rence was similar (p 0.5). This meant that patients returned
each time to the somewhat higher early post-treatment risk of
death. Although the cumulative effect of these recurring risks
for mortality might adversely affect survival, for patients
receiving induction chemoradiotherapy, survival was similar
whether or not complications occurred (p log-rank  0.5);
the same was true of patients who did not receive induction
chemoradiotherapy (p log-rank  0.2). Severity of compli-
cations, expressed as requirement for surgical intervention,
did not affect survival, whether or not induction chemoradio-
therapy was used (p early hazard phase 0.9, p late hazard
phase  0.5).
TABLE 3. Number of Benign Pleural or Pericardial
Complications per Patient
Complication
Induction
Chemoradiotherapy
(% of 100)
Surgery Only
(% of 100)
Pleural effusion
0 44 54
1 38 34
2 12 10
3 or more 6 2
No. of complications 86a 61a
Pericardial effusion
0 79 91
1 or more 21 9
No. of complications 25a 9a
Pericarditis
0 94 98
1 or more 6 2
No. of complications 7a 2a
Any pleural or pericardial complication
0 39 54
1 36 28
2 9 12
3 8 5
4 or more 8 1
Total complications 118 72
a Total number of each type of complication experienced during follow-up.
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FIGURE 1. Freedom from benign pleural or peri-
cardial complications after esophagectomy ac-
cording to whether or not induction chemoradio-
therapy (ICRT) had been administered
(propensity-matched patients). Symbols represent
first-occurring complication, vertical bars 68%
confidence limits (CL) equivalent to 1 standard
error, and numbers in parentheses patients re-
maining at risk (Kaplan-Meier product limit esti-
mates16). Solid lines enclosed within dashed CLs
represent parametric estimates.15
FIGURE 2. Benign pleural or pericardial compli-
cations after esophagectomy, according to
whether or not induction chemoradiotherapy
(ICRT) had been administered (propensity-
matched patients). Analysis includes all ICRT
events. A, Incidence (hazard function15). Dashed
lines represent 68% confidence limits (CL). B, Cu-
mulative incidence. Symbols represent individual
events, vertical bars nonparametric 68% confi-
dence limits, and numbers in parentheses patients
remaining at risk (Nelson cumulative hazard re-
peating event method17). Solid lines are parametric
estimates enclosed within dashed 68% CLs.15
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FIGURE 3. Cumulative incidence of benign pleu-
ral effusion after esophagectomy, according to
whether or not induction chemoradiotherapy
(ICRT) had been administered (propensity-
matched patients). Format is as in Figure 2B.
FIGURE 4. Benign pericardial complications
(pericardial effusion or pericarditis) after esopha-
gectomy, according to whether or not induction
chemoradiotherapy (ICRT) had been administered
(propensity-matched patients). Format is as in Fig-
ure 2. A, Incidence. B, Cumulative incidence.
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DISCUSSION
Principal Findings
Complication Occurrence and Timing
Locally advanced esophageal cancer portends an omi-
nous prognosis. Because of this, attempts to combine thera-
pies, both in the induction (preoperative) and consolidation
(postoperative) settings, have experienced a renaissance. To
date, however, the efficacy of multimodality treatments, in-
corporating surgical resection as their thrust, have yielded
fairly disappointing results, with, at best, minimal improve-
ment in survival.2,6
Regardless of impact on survival, it has often been
reported that induction chemoradiotherapy for locally ad-
vanced esophageal cancer is well tolerated and is not accom-
panied by additional perioperative morbidity.5,22 Although
these conclusions seemed difficult to accept, it is easy to
conceive that a small additional morbidity caused by induc-
tion chemoradiotherapy could be statistically unrecognized in
the setting of esophagectomy only—an enormously morbid
procedure by itself. What has been overlooked are late man-
ifestations of induction chemoradiotherapy. We were there-
fore surprised to find what appeared to be an extraordinary
number of benign pleural and pericardial complications con-
tributing to late morbidity in our series of patients with
advanced-stage esophageal cancers.
Assessing these complications is not a simple task,
however. They are time related, but analysis must account for
the competing risk of death and mandates vigilant follow-up.
Nonetheless, we have undertaken this task and can now
demonstrate that induction chemoradiotherapy does indeed
increase morbidity, specifically, postesophagectomy benign
pleural and pericardial complications, which often required
intervention to control, but appeared to have little demonstra-
ble impact on patient survival.
Influence of Induction Chemoradiotherapy on
Complications
This study was not designed to determine a clinical
benefit from our induction chemoradiotherapy regimen; that
has been reported earlier.8–10 Rather, our intent was to dis-
cover a reason for the increasing pleural and pericardial
complications observed after esophagectomy. Induction che-
moradiotherapy impressively increased early risk of these
benign pleural and pericardial complications, translating into
nearly a twofold higher incidence within the first year. The
FIGURE 5. Survival following esophagectomy,
before and after occurrence of pleuropericardial
complications. Format is as in Figure 2. Open cir-
cles represent survival before the competing risk
of a pleuropericardial complication and closed
circles survival after a complication.
TABLE 4. Interventions for Benign Pleural and Pericardial Complications
Intervention
Complications
Pleural Effusion Pericardial Effusion Pericarditis Any Complication
ICRT Surgery Only ICRT Surgery Only ICRT Surgery Only ICRT Surgery Only
Intervention performeda 50 (58) 31 (51) 12 (48) 2 (22) 6 (86) 1 (50) 68 (58) 34 (47)
Intervention typeb
Medical 45 (90) 24 (77) 7 (58) 1 (50) 4 (67) 0 (0) 56 (82) 25 (74)
Surgical 1 (2) 0 (0) 5 (42) 1 (50) 2 (33) 1 (100) 8 (12) 2 (6)
Medical and surgical 4 (8) 7 (23) 0 (0) 0 (0) 0 (0) 0 (0) 4 (6) 7 (21)
Total complications 86 61 25 9 7 2 118 72
a Number and, in parentheses, percent of complications.
b Number and, in parentheses, percent of interventions.
ICRT, induction chemoradiotherapy.
Journal of Thoracic Oncology • Volume 4, Number 3, March 2009 Pleural and Pericardial Complications
Copyright © 2009 by the International Association for the Study of Lung Cancer 401
greatest risk was for pericardial complications, with a more
than fivefold incidence above that observed with esophagec-
tomy only.
We suspect that additional toxicity of induction che-
moradiotherapy is attributable primarily to mediastinal radi-
ation, with perhaps a sensitizing effect of chemotherapy,
although we cannot discount a possible contribution from
malnutrition or protein-losing enteropathy. The effects of
ionizing radiation on mediastinal structures are complex.
Radiation-induced heart disease, pneumonitis, and pleuritis
have been documented in both acute and chronic settings 23–26.
These complications occur frequently when chemoradiother-
apy is used as primary therapy for mediastinal cancer. In fact,
echocardiographic evidence of pericardial disease can be
observed in 40% of patients followed at least 5 years after
mediastinal lymphoma treatment.27
There is little doubt that esophagectomy itself, without
chemoradiotherapy, is a risk factor for these complications,
although this could not be evaluated against chemoradio-
therapy alone. Patients in the series had locally advanced
adenocarcinoma of the esophagus and, regardless of
whether induction chemoradiotherapy was given, under-
went esophagectomy with en bloc abdominal and posterior
mediastinal (two-field) lymphadenectomy.7 Moreover, the
thoracic duct was often resected, although the posterior peri-
cardium was always left intact. Disruption of lymphatic
channels investing the region was likely complete, and con-
sequently, it is not surprising that pleural or pericardial
effusion complicated the postoperative course to some degree
even in the absence of induction chemoradiotherapy.
Treatment
Particularly troubling is that these pleural and pericar-
dial complications following esophagectomy for cancer are
not simply nuisances that abate spontaneously; they often
persist and require intervention. This seems particularly true
when induction chemoradiotherapy is given, although the
data are inconclusive on this point. A brief, early report
documented 15% reintervention for general pleural and peri-
cardial complications among patients surviving at least 5
months after induction chemoradiotherapy and esophagec-
tomy for squamous cell cancer.28
Although most of the interventions were uncomplicated
aspirations, delay in diagnosing slowly worsening pleural
effusion may have led to more complex operative interven-
tions in some patients. Because of this, after early postesoph-
agectomy recovery, patients who receive induction chemora-
diotherapy are now routinely seen at 3-month intervals, with
chest imaging for 2 years and then every 6 months up to 5
years. In the absence of specific heart imaging, any concern-
ing auscultatory finding (e.g., rub, muffled tones) mandates
echocardiography. It has more recently become our practice
that patients who redevelop pleural effusion after thoracen-
tesis proceed to thoracoscopy and pleurodesis in an attempt to
prevent entrapped lung syndrome.
Surprisingly, depending on the degree of pleuritis and
pleural fibrosis induced by radiation, chemical pleurodesis is
often ineffective in palliating recurrent benign pleural effu-
sion after induction chemoradiotherapy. The avascular,
densely fibrotic parietal pleura over the lower hemithorax
does not provide a good substrate for pleural symphysis. In
these cases, it may be prudent to add a local pleurectomy,
because this exposes the healthier, better vascularized endo-
thoracic fascial layer as the adherent surface. It is conceivable
that these patients can be recognized by preoperative imaging
studies.
Influence of Complications on Subsequent Survival
Occurrence of each complication seems to expose the
patient to a transient period of high risk that quickly subsides
and returns to a precomplication level. Among the patients in
this study, the number of occurrences and recurrences has
been insufficient to suggest a survival impact. However, it is
conceivable that a small deleterious effect on survival may be
hidden, given the overwhelming risk of death from cancer
recurrence in these patients.
Limitations
We interpreted pleural and pericardial complications as
benign when cytology was available and they resolved, or
were not followed by cancer recurrence elsewhere. This may
overestimate occurrence of these complications, because
some could have been malignant (false positives), which
would, in turn, underestimate cancer recurrence.
It is comforting to note that there was little survival
difference between patients with and without pleural and
pericardial complications, which supports our contention that
these are benign occurrences.
An important limitation is that patients were not ran-
domly assigned to receive induction chemoradiotherapy. De-
cision to use induction chemoradiotherapy was not protocol-
ized, at times it was not available, and occasionally patients
declined it. This resulted in considerable heterogeneity in
cancer stage among patients undergoing surgery alone and
those receiving induction chemoradiotherapy. This overlap of
patient and cancer characteristics allowed us to use an ap-
proximate randomized study design to explore whether in-
duction chemoradiotherapy increased risk of these complica-
tions. All but 6 patients receiving chemoradiotherapy could
be matched. Further, patients tolerate induction chemoradio-
therapy differently with regard to threshold of toxicity devel-
opment. This clearly affects the absolute amount of induction
treatment that can be delivered to a specific patient and,
consequently, creates heterogeneity in the treatment group.
This problem cannot easily be accounted for in an analysis of
this limited size, despite including total dose of radiation and
number of chemotherapy cycles completed as variables.
This was a single-institution study, which permitted
in-depth review of these complications, but may limit gener-
alizability. We are also uncertain of the generalizability of
these findings because induction chemoradiotherapy regi-
mens among institutions vary.
CONCLUSIONS
Perioperative and immediate postoperative complica-
tions of esophageal resection performed after induction che-
moradiotherapy have been chronicled elsewhere.9,29 Particu-
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larly concerning are problems arising well after apparent
recovery that continue to contribute to morbidity and that
may ultimately reduce efficacy of multimodality treatment
regimens. Of importance, these are seldom documented or
captured during the short follow-up afforded most patients
because of the competing risk of death from cancer recur-
rence that tends to confound the latent appearance of benign
complications.
When documented early, aggressive management
may avoid subsequent extensive operative interventions.
These insidious complications must be discussed with
patients as possible risks when considering enrollment in
induction chemoradiotherapy protocols for locally ad-
vanced esophageal cancer and are distinctly different from
the acute toxicities of multimodality therapy that are stan-
dardly reported.
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APPENDIX: VARIABLES EXAMINED IN
MULTIVARIABLE ANALYSES
Demography: Age, sex
Preoperative therapy: Paclitaxel  cisplatin (cycles),
5-fluorouracil  cisplatin (cycles), radiation dose
(Gy), any chemoradiotherapy
Tumor characteristics: Adenocarcinoma, squamous cell
carcinoma, histologic grade (G) (well differentiated,
moderately differentiated, poorly differentiated/un-
differentiated)
Clinical stage: IIA, IIB, III/IVa
Pathologic stage: All stages, down-staged (yes/no)
Postoperative therapy: Paclitaxel  cisplatin (cycles),
5-fluorouracil  cisplatin (cycles), radiation dose
(Gy), any chemoradiotherapy
Procedure: Date of esophagectomy
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